Medical researchers are pioneering a fundamental shift in cancer care, moving from treating advanced tumors to intercepting the disease decades before it fully develops. This proactive strategy, known as cancer interception, aims to identify and target the earliest biological warning signs of cancer, potentially preventing the illness altogether.
The approach is built on the understanding that cancer is not a sudden event but a slow, multi-step process. Scientists are identifying subtle early warnings, including genetic mutations that accumulate in cells and precancerous lesions like certain polyps. Large genetic studies have revealed that as people age, they acquire small groups of mutated cells called clones. Research, particularly in blood cancers, shows these clones can help predict who might later develop diseases like leukaemia, influenced by genetics, inflammation, and environment. A key 16-year study of around 7,000 women demonstrated how specific mutations make these clones multiply faster or become sensitive to inflammation, providing a measurable pattern to track over time.
A leading tool in this effort is the development of multi-cancer early detection (MCED) blood tests. These tests search for circulating tumour DNA (ctDNA), fragments shed by cancerous or precancerous cells into the bloodstream. Early results are promising, especially for cancers like colorectal cancer where early detection drastically improves outcomes. When diagnosed at stage one, 92% of colorectal cancer patients survive five years, compared to only 18% when caught at stage four. However, the tests are not yet perfect, sometimes missing cancers or requiring confirmatory scans and biopsies for positive results.
Navigating the Promise and Challenges of Prevention
Researchers envision a future model similar to heart disease prevention, where a person’s risk—calculated from genetic, environmental, and MCED data—guides early intervention. However, cancer presents unique challenges: its progression is less predictable, and tools vary in effectiveness. A major concern is over-diagnosis, where identifying risk or non-progressive lesions causes unnecessary anxiety and procedures. Ethical questions also arise about intervening in healthy people and the potential for these tools to worsen health inequalities if they are costly or inaccessible.
Health systems are now grappling with how to integrate these advances safely. Regulatory bodies are investigating the required reliability of MCED tests and appropriate follow-up protocols. In England, the National Cancer Plan commits to providing 9.5 million extra diagnostic tests annually by 2029 and will extend ctDNA biomarker testing to more cancers if proven cost-effective. The collective work underscores a transformative insight: cancer begins long before symptoms appear, and intercepting it early holds the potential to save countless lives, provided it is implemented with careful consideration of efficacy and equity.